EP300
MOLECULAR TARGETEP300 lysine acetyltransferase
EP300 (EP300 lysine acetyltransferase) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting EP300
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | epigalocatechin gallate | 5.40 | 220 |
| 2 | berberine chloride | 4.56 | 95 |
| 3 | molibresib | 3.81 | 44 |
| 4 | anacardic acid | 3.09 | 21 |
| 5 | mivebresib | 3.00 | 19 |
| 6 | a 485 | 2.83 | 16 |
| 7 | gsk046 | 2.40 | 10 |
| 8 | palmitine | 2.40 | 10 |
| 9 | gsk620 | 2.30 | 9 |
| 10 | inobrodib | 2.20 | 8 |
| 11 | garcinol | 2.20 | 8 |
| 12 | gsk778 | 2.08 | 7 |
| 13 | plumbagin [Supplementary Concept] | 1.61 | 4 |
| 14 | egcg | 0.69 | 1 |
| 15 | 11-hydroxypalmatine [Supplementary Concept] | 0.69 | 1 |
About EP300 as a Drug Target
EP300 (EP300 lysine acetyltransferase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented EP300 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
EP300 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.